Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.
Huq S, Casaos J, Serra R, Peters M, Xia Y, Ding AS, Ehresman J, Kedda JN, Morales M, Gorelick NL, Zhao T, Ishida W, Perdomo-Pantoja A, Cecia A, Ji C, Suk I, Sidransky D, Brait M, Brem H, Skuli N, Tyler B.
Huq S, et al. Among authors: cecia a.
Mol Cancer Ther. 2020 Sep;19(9):1797-1808. doi: 10.1158/1535-7163.MCT-19-0572. Epub 2020 Jun 30.
Mol Cancer Ther. 2020.
PMID: 32606016